Cormedix is a specialty pharmaceutical company that develops products to treat cardiac, renal and infectious diseases.
We seek to license and develop product candidates that have been previously tested in human clinical trials or marketed elsewhere for different indications. This provides evidence of a drug's safety and biological activity, thereby reducing potential development risks. We ultimately plan to either out-license, partner, or build a specialty sales force to market and promote our products throughout the world. We are an internationally focused company that is mindful of the potential global opportunities for our products. Our management has a proven track record of developing, registering, pricing/reimbursing, and successfully selling medicines, biologics and devices. We are supported by expert managerial and scientific advisory boards.
Our foundational technology prevents infection and clotting that can occur with the use of chronic CVCs (central venous catheters). Chronic CVCs are frequently used in the life-sustaining "artificial kidney" process known as hemodialysis (HD). CVCs are also used in patients receiving chemotherapy, chronic antibiotic therapy, total parenteral nutrition or intensive care.
Medical experts consider infection from chronic CVCs to be the chief source of morbidity - and a major source of mortality - in HD patients. We have identified, licensed and advanced two products that are designed to keep implanted chronic CVCs infection-free and fully flowing:
- CRMD003 (Neutrolin®) — an antimicrobial/anticoagulant solution; and
- CRMD004 — a "thixotropic" gel that changes from a semi-solid to a free-flowing liquid under the pressure of insertion into (or withdrawal from) a catheter.